06.17.25 -- What Biotechs Learn From Takeda's Internal Manufacturing Competition

Discover how Catalent’s UpTempo℠ Plasmid Platform is transforming plasmid DNA manufacturing for cell and gene therapies. Join this expert-led webinar to learn how this innovative solution accelerates development timelines, enhances yields, and simplifies supply chains. Gain valuable insights into overcoming common manufacturing challenges and the benefits of a streamlined, one-stop approach. Click here to learn more.

Review different aspects of container selection from the perspective of cryopreservation that may be overlooked but are critical for the quality of cell therapy drug products.

Leveraging the expertise of a chosen clinical supply partner can be a valuable resource. Examine key considerations when partnering with a CRO in order to deliver a successful clinical supply strategy.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

Jumai Abioye, Founder and CEO, Pan Access Innovations Inc. provides opening comments on CMC needs and gaining support from your CDMOs.

Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

Boost rAAV yields and quality while reducing costs with the HEK293 cell line and scalable, optimized manufacturing platform for gene therapy.

Learn how scalable innovation is transforming viral vector production and driving broader, more equitable access to advanced gene therapies.

By leveraging cells equipped with an existing landing pad, explore how inducible expression can be efficiently achieved within just four to six weeks after donor plasmid creation.

To support the growing demands of the ATMP industry, it's essential to leverage integrated biostorage, sample management, and regulatory solutions, and we are committed to enhancing these capabilities.

The QA team at a cell therapy CDMO ensures all aspects of development and manufacturing meet the highest standards of quality, safety, and regulatory compliance.

Consider this reliable solution for labeling small batches of medical products, including vials, syringes, and cartridges, that fully automatic machines struggle to handle for your next project.

Investigate a powerful suite of proprietary gene editing technology to accelerate the development of life-changing and curative therapies.

Witness how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.

With experience in microbial fermentation and a commitment to scientific precision, we have developed a solid foundation that supports effective results for our partners.

Director of Commercial Development, Serat Ali, describes FDB's Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.

Manufacturing services are powered by the advanced Pro10™ platform, which has produced over 1000 successful batches of high-quality vectors crucial for gene therapy research.

Our advanced, modular AAV manufacturing platform is continuously evolving to adapt to developer needs and the ever-changing regulatory landscape.